Surgical Sample Collection- Sampling During Uterine Surgery
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: VP, Clinical Operations
- Phone Number: 463-273-7024
- Email: devon@pinkdx.com
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
-
Texas
-
Houston, Texas, United States, 77030
- Houston Methodist
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Evidence of a personally signed and dated informed consent form (ICF) indicating that the participant has been informed of all pertinent aspects of the study.
- Willing and able to comply with scheduled visits, investigational plan, and other procedures.
Females:
- Aged >45 for benign and pre-malignant cases
- Aged >18 with positive biopsies.
- Presence of uterus.
- Scheduled for hysterectomy.
Exclusion Criteria:
- Investigator site staff members directly involved in the conduct of the study and their family members or participants who are Pink Dx, Inc. employees or their family members.
- Other acute or chronic medical or psychiatric conditions that would increase the risk associated with study participation in the judgement of the investigator.
- Women who have undergone a hysterectomy.
- Inability or unwillingness to sign informed consent.
- Contraindication to surgery, including pregnancy.
- Women who have used a tampon within 7 days of surgery.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
benign
tissue collection from women with benign reproductive conditions
|
|
malignant
tissue collection from women with suspected and malignant reproductive conditions
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with optimal vaginal samples obtained during the collection process
Time Frame: 9 months
|
Number of participants with optimal vaginal samples obtained during the collection process, including preferred anatomical location and yields and quality of samples.
|
9 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Andrea Mariani, MD, Mayo Clinic
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- PNK001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.